REAL-WORLD EVIDENCE FOR CLINICAL EFFECTIVENESS, TOXICITY, AND HOSPITALIZATION COSTS ASSOCIATED WITH SECOND-LINE CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
机构：[1]Department Of Respiratory Medicine, Xiangya Hospital, The Central South University,China,[2]Department Of Medical Oncology, Cancer Institute (hospital), Chinese Academy Of Medical Sciences And Peking Union Medical College,China,[3]Medical Oncology, Hunan Province Tumor Hospital, Central South University,China,[4]Education And Research, Hunan Province Tumor Hospital, Central South University,China,[5]Clinical Pharmacy, Xuanwu Hospital, Capital Medical University,China,首都医科大学宣武医院[6]Lilly Suzhou Pharmaceutical Co., Ltd,China,[7]Global Health Outcomes Research, Eli Lilly,United States Of America,[8]Normin Health Changsha Office,China,[9]Leslie Dan Faculty Of Pharmacy,University Of Toronto, Canada
第一作者机构：[1]Department Of Respiratory Medicine, Xiangya Hospital, The Central South University,China,
推荐引用方式(GB/T 7714)：
Cheng Ping Hu,Yan Wang,Jianhua Chen,et al.REAL-WORLD EVIDENCE FOR CLINICAL EFFECTIVENESS, TOXICITY, AND HOSPITALIZATION COSTS ASSOCIATED WITH SECOND-LINE CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER[J].JOURNAL OF THORACIC ONCOLOGY.2013,8:S587-S588.
APA：
Cheng Ping Hu,Yan Wang,Jianhua Chen,Shengqi Wu,Xiaoling Li...&Wendong Chen.(2013).REAL-WORLD EVIDENCE FOR CLINICAL EFFECTIVENESS, TOXICITY, AND HOSPITALIZATION COSTS ASSOCIATED WITH SECOND-LINE CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.JOURNAL OF THORACIC ONCOLOGY,8,
MLA：
Cheng Ping Hu,et al."REAL-WORLD EVIDENCE FOR CLINICAL EFFECTIVENESS, TOXICITY, AND HOSPITALIZATION COSTS ASSOCIATED WITH SECOND-LINE CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER".JOURNAL OF THORACIC ONCOLOGY 8.(2013):S587-S588
医学